BioInvent Presents Positive Data for BI-505 at International Myeloma Congress

Lund, Sweden – 4 April 2013 – BioInvent International AB (OMXS:BINV) announce
that the previously communicated positive results from a phase I trial of BI-505
is presented today at The International Myeloma Workshop in Kyoto, Japan. At the
same meeting, preclinical data is also presented which demonstrate significantly
enhanced efficacy when approved myeloma drugs are combined with BI-505. BI-505
is a human antibody directed against ICAM-1 and is developed for the treatment
of multiple myeloma.

The results from the phase I study of BI-505 in patients with advanced multiple
myeloma are presented by Associate Professor Markus Hansson at Lund University.
The preliminary analysis shows that BI-505 has an advantageous safety profile.
In cohorts where extended treatment was available, 24 percent of the patients
had stable disease for at least two months, indicating effect of BI-505.

At the same meeting, new preclinical data is also presented showing
significantly enhanced anti-myeloma activity when the approved drugs Velcade® or
Revlimid® is combined with BI-505 compared to single agent treatment. Combined
treatment was evaluated in two different experimental models and the drugs were
given in a similar way as to patients with myeloma. In one of the models
enhanced survival was observed following combination therapy with BI-505,
compared to single agent treatment with the approved drugs. In the second model,
complete remission was observed in the majority of animals when combining BI-505
with Revlimid® or Velcade®.

Cristina Glad, CEO for BioInvent, commented: “We believe BI-505 has the
potential to address a major unmet medical need in a broad population of
patients with multiple myeloma. Based on the results from the phase I trial
which are now presented at the international myeloma meeting, we have decided to
continue our studies on BI-505 with a new smaller trial in patients with
asymptomatic multiple myeloma (called “smoldering multiple myeloma”). The
interesting preclinical studies showing enhanced anti-tumor effect when
combining BI-505 with approved drugs, support to move forward with a clinical
trial in which BI-505 is combined with another drug, representing a logic
continuation of the clinical development process for our hitherto most advanced
project.”

-- END --

Background information:

About BI-505
The candidate drug BI-505 is a human antibody that specifically binds to the
ICAM-1 adhesion protein (also known as CD54). Expression of ICAM -1 is increased
on myeloma cells, which makes it a suitable target for a candidate drug. BI-505
exerts its antimyeloma activity by inducing programmed cell death in myeloma
cells and by engaging patient´s immune cells to attack myeloma cells. In several
animal models, BI-505 has been shown to kill tumor cells more efficiently than
existing drugs.

The first results from the phase I study of BI-505 in patients in advanced
stages of the malignant disease multiple myeloma were reported earlier this
year. The preliminary analysis showed that BI-505 has an advantageous safety
profile. In dose groups where extended therapy was offered, 24% of these
severely ill patients demonstrated stable disease for at least two months,
indicating effect of BI-505.

The number of newly diagnosed patients with multiple myeloma worldwide is
estimated to more than 40,000 per year.

BI-505 has received Orphan Drug Designation in both Europe and the US for the
indication multiple myeloma. This provides BioInvent with market exclusivity for
treatment of multiple myeloma with an antibody against ICAM-1 for up to 10 years
after marketing approval is granted.

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a
research-based pharmaceutical company focused on discovery and development of
innovative antibody-based drugs against cancer. The Company's pipeline currently
includes three product candidates for the treatment of cancer.

The company's competitive position is underpinned by n-CoDeR®, a proprietary
antibody development platform. The scope and strength of this platform is also
used to develop antibody-based drugs in collaboration with partners who finance
the development of the new drug, and provide BioInvent the right to milestone
payments and royalties on sales. These partners include Bayer HealthCare,
Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at
www.bioinvent.com.

For further information, please contact:
Cristina Glad
President and CEO
+46 (0)46 286 85 51
+46 (0)708 16 85 70
cristina.glad@bioinvent.com

The Trout Group
Christine Yang
Vice President
Phone: +1 646 378 2929
E-mail: cyang@troutgroup.com

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com


Legal disclaimer
The press release contains statements about the future, consisting of subjective
assumptions and forecasts for future scenarios. Predictions for the future only
apply as the date they are made and are, by their very nature, in the same was
as research and development work in the biotech segment, associated with risk
and uncertainty. With this in mind, the actual outcome may deviate significantly
from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the
Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading
Act. The information was submitted for publication at 8.30 a.m. CET on April 4,
2013.